Restoration of chemosensitivity in cancer cells with MDR phenotype by deoxyribozyme, compared with ribozyme

Experimental and Molecular Pathology

Volumn 94, Issue 3, 2013, Pages 481-485

  Xing, Ai Yan ^a   Shi, Duan Bo ^a   Liu, Wei ^a,b   Chen, Xu ^a   Sun, Yan Lin ^a   Wang, Xiao ^a   Zhang, Jian Ping ^a   Gao, Peng ^a  

^a SHANDONG UNIVERSITY   (China)

^b TENGZHOU CENTRAL PEOPLE S HOSPITAL   (China)

Author keywords

ASODN; Multidrug resistance; P glycoprotein; Suppress; Transfection

Indexed keywords

ADENINE; ANTISENSE OLIGONUCLEOTIDE; DEOXYRIBOZYME; DOXORUBICIN; GUANINE; HYDROXYUREA; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHOROTHIOIC ACID; RHODAMINE 123; RIBOZYME; URIDINE; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CHEMOSENSITIVITY; CODON; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; PHENOTYPE; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSLATION INITIATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA, CATALYTIC; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; OLIGONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; TRANSFECTION; VINBLASTINE;

EID: 84876314293     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.03.004     Document Type: Article

References (29)

1. Beigelman L., McSwiggen J.A., Draper K.G. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. Journal of Biological Chemistry 1995, 270:25702-25708.
2. Brown T., Mackey K. Analysis of RNA by Northern and slot blot hybridization. Current Protocols of Molecular Biology 1997, John Wiley & Sons, New York. V.B. Chanda (Ed.).
3. Cairns M.J., Hopkins T.M., Witherington C., et al. The influence of arm length asymmetry and base substitution on the activity of the 10-23 DNA enzyme. Antisense & Nucleic Acid Drug Development 2000, 10:323-332.
4. Chen X., Li N., Ellington A.D. Ribozyme catalysis of metabolism in the RNA world. Chemistry and Biodiversity 2007, 4:633-655.
5. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 1987, 162:156-159.
6. Fojo T., Bates S. Strategies for reversing drug resistance. Oncogene 2003, 22:7512-7523.
7. Gao P., Zhou G.Y., Zhang Q.H. Reversal MDR in breast carcinoma cells by ribozyme designed according the secondary structure of mdr1 mRNA. Chinese Journal of Physiology 2006, 49:96-103.
8. Gao P., Zhou G.Y., Guo L.L., et al. Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter. Cancer Letters 2007, 256:81-89.
9. Gatouillat G., Odot J., Balasse E. Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells. Cancer Letters 2007, 257:165-171.
10. Giannini C.D., Roth W.K., Piiper A., et al. Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture. Nucleic Acids Research 1999, 27:2737-2744.
11. Holm P.S., Scanlon K.J., Dietel M. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. British Journal of Cancer 1994, 70:239-243.
12. Huang Y., Sadee W. Membrane transporters and channels in chemoresistance and sensitivity of tumor cells. Cancer Letters 2006, 239:168-182.
13. Huesker M., Folmer Y., Schneider M., et al. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes. Hepatology 2002, 36:874-884.
14. Jen K.Y., Gewirtz A.M. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies. Stem Cells 2000, 18:307-319.
15. Kobayashi H., Dorai T., Holland J.F., et al. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Research 1994, 54:1271-1275.
16. Kurreck J., Bieber B., Jahnel R., et al. Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. Biological Chemistry 2002, 277:7099-7107.
17. Kuwabara T., Warashina M., Tanabe T., et al. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Research 1997, 25:3074-3081.
18. Marzolini C., Paus E., Buclin T., et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics 2004, 75:13-33.
19. Mercola D., Cohen J.S. Antisense approaches to cancer gene therapy. Cancer Gene Therapy 1995, 2:47-59.
20. Motomura S., Motoji T., Takanashi M. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (MDR1) antisense oligonucleotides. Blood 1998, 91:3163-3171.
21. Peer D., Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Letters 2006, 237:180-187.
22. Ramachandran C., Wellham L.L. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts. Anticancer Research 2003, 23:2681-2690.
23. Santiago F.S., Lowe H.C., Kavurma M.M., et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nature Medicine 1999, 5:1438.
24. Santoro S.W., Joyce G.F. A general purpose RNA-cleaving DNA enzyme. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:4262-4266.
25. Schubert S., Gul D.C., Grunert H.P., et al. RNA cleaving '10-23' DNAzymes with enhanced stability and activity. Nucleic Acids Research 2003, 31:5982-5992.
26. Sioud M., Leirdal M. Design of nuclease resistant protein kinase calpha DNA enzymes with potential therapeutic application. Journal of Molecular Biology 2000, 296:937-947.
27. Thierry A.R., Dritschilo A. Liposomal delivery of antisense oligodeoxynucleotides. Application to the inhibition of the multidrug resistance in cancer cells. Annals of the New York Academy of Sciences 1992, 660:300-302.
28. Turner P.C. Ribozymes: their design and use in cancer. Advances in Experimental Medicine and Biology 2000, 465:303-318.
29. Zhang X., Xu Y., Ling H., Hattori T. Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme. FEBS Letters 1999, 458:151-156.